The first interim analysis of the results of Phase 3 clinical trials of Pfizer and BioNTech vaccine showed its effectiveness at the level of more than 90% in preventing COVID-19 disease in those who were not previously infected with the virus. The partners plan to request FDA approval for use in emergency situations soon after sufficient data on drug safety has been accumulated in the second half of November.